Colleen Cutcliffe

Colleen Cutcliffe is the Chief Executive Officer and co-founder of Pendulum Therapeutics, a startup company based in San Francisco that uses biological and computational insights into the microbiome to develop interventions for a variety of health and disease conditions. Using this discovery platform, Pendulum has created the world's first microbiome intervention for people with Type 2 Diabetes that has been clinically shown to reduce A1C and postprandial glucose response.

She has more than 15 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Cutcliffe's scientific foundation is particularly strong: she received her PhD in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College. She completed her postdoctoral studies at Northwestern's Children's Memorial Hospital.

Career history

• Senior Manager of Biology at Pacific Biosciences (where she met her two co-founders)
• Scientist at Elan Pharmaceuticals
• Postdoctoral researcher at Northwestern's Children's Memorial Hospital
• PhD researcher in Biochemistry and Molecular Biology, Johns Hopkins University

What Cutcliffe could bring to her CEO role at Pendulum Therapeutics: Her unique combination of deep scientific expertise in biochemistry and molecular biology, coupled with extensive experience managing biology teams across academia and the pharmaceutical sector, positions her to bridge the gap between cutting-edge microbiome science and commercial viability. Her demonstrated ability to embrace the chaos inherent in startup innovation and her transparent leadership approach enable her to drive Pendulum's mission of creating clinically-validated microbiome products with pharmaceutical efficacy and probiotic accessibility.

This is an automatically generated Light profile created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.